ADMA Biologics Management
Management criteria checks 3/4
ADMA Biologics' CEO is Adam Grossman, appointed in Jan 2007, has a tenure of 17.92 years. total yearly compensation is $6.04M, comprised of 12.4% salary and 87.6% bonuses, including company stock and options. directly owns 1.05% of the company’s shares, worth $43.03M. The average tenure of the management team and the board of directors is 0.9 years and 10.5 years respectively.
Key information
Adam Grossman
Chief executive officer
US$6.0m
Total compensation
| CEO salary percentage | 12.4% |
| CEO tenure | 17.9yrs |
| CEO ownership | 1.0% |
| Management average tenure | less than a year |
| Board average tenure | 10.5yrs |
Recent management updates
Recent updates
ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV
Dec 02Subdued Growth No Barrier To ADMA Biologics, Inc. (NASDAQ:ADMA) With Shares Advancing 36%
Nov 26
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues
Oct 09ADMA Biologics: Riding High On ASCENIV's Success
Oct 02ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Sep 06ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
Aug 16ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Jul 27ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 24Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
May 30ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics: A Path To Profits Looks Clear
May 12ADMA: Pertinent Updates
Apr 18ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Mar 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$68m |
| Jun 30 2024 | n/a | n/a | US$35m |
| Mar 31 2024 | n/a | n/a | -US$4m |
| Dec 31 2023 | US$6m | US$750k | -US$28m |
| Sep 30 2023 | n/a | n/a | -US$23m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$48m |
| Dec 31 2022 | US$3m | US$637k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$70m |
| Jun 30 2022 | n/a | n/a | -US$73m |
| Mar 31 2022 | n/a | n/a | -US$78m |
| Dec 31 2021 | US$4m | US$618k | -US$72m |
| Sep 30 2021 | n/a | n/a | -US$74m |
| Jun 30 2021 | n/a | n/a | -US$74m |
| Mar 31 2021 | n/a | n/a | -US$75m |
| Dec 31 2020 | US$2m | US$600k | -US$76m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$61m |
| Mar 31 2020 | n/a | n/a | -US$54m |
| Dec 31 2019 | US$2m | US$536k | -US$48m |
| Sep 30 2019 | n/a | n/a | -US$56m |
| Jun 30 2019 | n/a | n/a | -US$59m |
| Mar 31 2019 | n/a | n/a | -US$61m |
| Dec 31 2018 | US$2m | US$536k | -US$66m |
| Sep 30 2018 | n/a | n/a | -US$61m |
| Jun 30 2018 | n/a | n/a | -US$61m |
| Mar 31 2018 | n/a | n/a | -US$55m |
| Dec 31 2017 | US$3m | US$494k | -US$44m |
Compensation vs Market: Adam's total compensation ($USD6.04M) is about average for companies of similar size in the US market ($USD6.65M).
Compensation vs Earnings: Adam's compensation has been consistent with company performance over the past year.
CEO
Adam Grossman (47 yo)
17.9yrs
Tenure
US$6,039,649
Compensation
Mr. Adam S. Grossman serves as Director at BioFlorida Inc since August 2021. He is the Co-Founder of ADMA Biologics, Inc. and has been its Chief Executive Officer and President since October 2011 and 2007...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 17.9yrs | US$6.04m | 1.05% $ 43.0m | |
| Co-Founder & Vice Chairman of the Board | 17.9yrs | US$284.72k | 0.22% $ 8.9m | |
| CFO & Treasurer | less than a year | no data | 0.084% $ 3.5m | |
| COO & Senior VP of Compliance | less than a year | no data | 0.055% $ 2.2m | |
| Vice President of Marketing & Corporate Development | no data | no data | no data | |
| Executive Director of Sales | less than a year | no data | no data | |
| Vice President of Human Resources | 2.9yrs | no data | no data | |
| Senior Director of Business Development & Corporate Strategy | no data | no data | no data |
0.9yrs
Average Tenure
49yo
Average Age
Experienced Management: ADMA's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 17.9yrs | US$6.04m | 1.05% $ 43.0m | |
| Co-Founder & Vice Chairman of the Board | 17.9yrs | US$284.72k | 0.22% $ 8.9m | |
| Independent Chairman | 17.9yrs | US$290.22k | 0.027% $ 1.1m | |
| Independent Director | 3.2yrs | US$272.34k | 0.097% $ 4.0m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 12.4yrs | US$275.09k | 0.060% $ 2.5m | |
| Member of Scientific Advisory Board | 10.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 10.5yrs | no data | no data | |
| Independent Director | 1.2yrs | US$231.12k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
10.5yrs
Average Tenure
60.5yo
Average Age
Experienced Board: ADMA's board of directors are seasoned and experienced ( 10.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 07:58 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ADMA Biologics, Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Sheshadri N. | Crisp Idea |
| Raghuram Selvaraju | H.C. Wainwright & Co. |